Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients

Biomarkers

Volumn 17, Issue 8, 2012, Pages 738-744

  Song, Tae Jin ^a   Kim, Jinkwon ^a   Yang, Seung Hee ^a   Park, Ji Hye ^a   Lee, Hye Sun ^a   Nam, Chung Mo ^a   Lee, Ok Hee ^a   Kim, Young Dae ^a   Nam, Hyo Suk ^a   Heo, Ji Hoe ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Functional outcome; Osteoprotegerin; Stroke; Stroke severity

Indexed keywords

BIOLOGICAL MARKER; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; ISCHEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPROTEGERIN; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84870502530     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.727027     Document Type: Article

References (30)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (Chicago, Ill.) 285:2486-2497.
2. American Diabetes Association (2004). Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl 1:S5-S10.
3. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. (1993). Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35-41.
4. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. (2011). ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 57:2037-2114.
5. Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J. (2007). Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 73:77-83.
6. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. (2006). Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26:2117-2124.
7. Browner WS, Lui LY, Cummings SR. (2001). Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637.
8. Chang KC, Lee HC, Tseng MC, Huang YC. (2010). Three-year survival after first-ever ischemic stroke is predicted by initial stroke severity: A hospital-based study. Clin Neurol Neurosurg 112:296-301.
9. Eriksson M, Norrving B, Terént A, Stegmayr B. (2008). Functional outcome 3 months after stroke predicts long-term survival. Cerebrovasc Dis 25:423-429.
10. Golledge J, McCann M, Mangan S, Lam A, Karan M. (2004). Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35:1636-1641.
11. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. (2007). Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 120:511-516.
12. Harari OA, Liao JK. (2010). NF-?B and innate immunity in ischemic stroke. Ann N Y Acad Sci 1207:32-40.
13. Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, Werkkala K, Kupari M. (2007). Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 9:357-363.
14. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S. (2001). Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280:334-339.
15. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL. (2010). Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 267:410-417.
16. Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, Liapis CD. (2008). The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 47:55-62.
17. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. (2004). Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175-2180.
18. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. (2006). The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4:801-811.
19. Lee BI, Nam HS, Heo JH, Kim DI; Yonsei Stroke Team. (2001). Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 12:145-151.
20. Nybo M, Johnsen SP, Dethlefsen C, Overvad K, Tjønneland A, Jørgensen JO, Rasmussen LM. (2008). Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. Clin Chem 54:1969-1974.
21. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. (2008). Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51:627-633.
22. Reid P, Holen I. (2009). Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88:1-17.
23. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park Jr. (2005). Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci 108:237-243.
24. Ridder DA, Schwaninger M. (2009). NF-kappaB signaling in cerebral ischemia. Neuroscience 158:995-1006.
25. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P. (2006). Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26:857-863.
26. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
27. Üstündag M, Orak M, Güloglu C, Tamam Y, Sayhan MB, Kale E. (2011). The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. J Int Med Res 39:780-789.
28. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, Hansen JB. (2011). Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. J Thromb Haemost 9:638-644.
29. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 95:3597-3602.
30. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. (2005). Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204:714-723.